Impact BioMedical, INC. Research and Development Expense
Impact BioMedical, INC. (IBO) reported Research and Development Expense of $76.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Impact BioMedical, INC. research and development expense for the quarter ending 2026-06-30 was $76.00K, a 1.33% increase year-over-year.
- Impact BioMedical, INC. research and development expense for the quarter ending 2026-03-31 was $46.00K, a 55.34% decline year-over-year.
- Impact BioMedical, INC. research and development expense for the quarter ending 2025-12-31 was $110.00K.
- Impact BioMedical, INC. research and development expense for the quarter ending 2025-09-30 was $52.00K, a 36.59% decline year-over-year.
- Impact BioMedical, INC. research and development expense for fiscal 2025 was $340.00K, a 22.30% increase from fiscal 2024.
- Impact BioMedical, INC. research and development expense for fiscal 2024 was $278.00K, a 83.50% decline from fiscal 2023.
- Impact BioMedical, INC. research and development expense for fiscal 2023 was $1.69M, a 37.44% increase from fiscal 2022.
- Impact BioMedical, INC. research and development expense for fiscal 2022 was $1.23M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $76.00K 10-Q · filed 2026-08-07 | $123.00K 10-Q · filed 2026-08-07 | $232.00K derived: sum of 3 quarters · filed 2026-08-07 | $284.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $46.00K 10-Q · filed 2026-05-12 | $156.00K derived: sum of 2 quarters · filed 2026-05-12 | $208.00K derived: sum of 3 quarters · filed 2026-05-12 | $283.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $162.00K derived: sum of 2 quarters · filed 2026-03-11 | $237.00K derived: sum of 3 quarters · filed 2026-08-07 | $340.00K 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | $52.00K 10-Q · filed 2025-11-07 | $127.00K derived: sum of 2 quarters · filed 2026-08-07 | $230.00K 10-Q · filed 2025-11-07 | $122.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $75.00K 10-Q · filed 2026-08-07 | $178.00K 10-Q · filed 2026-08-07 | $70.00K derived: sum of 3 quarters · filed 2026-08-07 | $152.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $103.00K 10-Q · filed 2026-05-12 | -$5.00K derived: sum of 2 quarters · filed 2026-05-12 | $77.00K derived: sum of 3 quarters · filed 2026-05-12 | $198.00K derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$26.00K derived: sum of 2 quarters · filed 2026-03-11 | $95.00K derived: sum of 3 quarters · filed 2026-03-11 | $278.00K 10-K · filed 2026-03-11 | ||||
| 2024-09-30 | $82.00K 10-Q · filed 2025-11-07 | $203.00K derived: sum of 2 quarters · filed 2025-11-07 | $386.00K 10-Q · filed 2025-11-07 | $1.02M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $121.00K 10-Q · filed 2025-08-14 | $304.00K 10-Q · filed 2025-08-14 | $50.00K 10-Q · filed 2024-08-13 | $934.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.29M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $183.00K 10-Q · filed 2025-05-14 | $50.00K 10-Q · filed 2024-05-10 | $813.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.17M derived: sum of 3 quarters · filed 2025-05-14 | $1.44M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $630.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $987.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.25M derived: sum of 3 quarters · filed 2025-03-28 | $1.69M 10-K · filed 2025-03-28 | $1.15M 10-K · filed 2024-02-20 | |||
| 2023-09-30 | $357.00K 10-Q · filed 2024-11-12 | $239.00K 10-Q · filed 2023-11-13 | $623.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.05M 10-Q · filed 2024-11-12 | $684.00K 10-Q · filed 2023-11-13 | $1.32M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $266.00K 10-Q · filed 2024-08-13 | $445.00K 10-Q · filed 2024-08-13 | $967.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.30M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $179.00K 10-Q · filed 2024-05-10 | $701.00K derived: sum of 2 quarters · filed 2024-05-10 | $1.03M derived: sum of 3 quarters · filed 2024-05-10 | $1.24M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $852.00K derived: sum of 2 quarters · filed 2024-02-20 | $1.06M derived: sum of 3 quarters · filed 2024-02-20 | $1.23M 10-K · filed 2024-02-20 | ||||
| 2022-09-30 | $330.00K 10-Q · filed 2023-11-13 | $536.00K derived: sum of 2 quarters · filed 2023-11-13 | $704.00K 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | $206.00K 10-Q · filed 2023-10-05 | $374.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |